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MicrogliaAbstract The DNA damage response (DDR) is a complex biological system activated by different
types of DNA damage. Mutations in certain components of the DDR machinery can lead to geno-
mic instability disorders that culminate in tissue degeneration, premature aging, and various types of
cancers. Intriguingly, malfunctioning DDR plays a role in the etiology of late onset brain degener-
ative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases. For many years, brain
degenerative disorders were thought to result from aberrant neural death. Here we discuss the evi-
dence that supports our novel hypothesis that brain degenerative diseases involve dysfunction of
glial cells (astrocytes, microglia, and oligodendrocytes). Impairment in the functionality of glial cells
results in pathological neuro-glial interactions that, in turn, generate a ‘‘hostile” environment that
impairs the functionality of neuronal cells. These events can lead to systematic neural demise on a
scale that appears to be proportional to the severity of the neurological deficit.The DNA damage response
The most serious threat to genome stability is damage inflicted
on DNA molecules [1]. Although DNA damage is usually
mentioned in connection with environmental agents, in fact
most of the ongoing damage to the cellular genome – estimatedaround tens of thousands of lesions each day – is caused by
endogenous reactive oxygen species (ROS) produced during
normal metabolism [1,2]. Proper action of the defense systems
that guard the genome against these ongoing threats is criti-
cally important for cellular homeostasis and development, as
well as prevention of undue cell loss, premature aging, and var-
ious types of malignancies [3,4]. These defense systems respond
to DNA lesions by activating specific DNA repair mecha-
nisms, which operate on a variety of DNA base lesions,
base-pair mismatches, crosslinks, as well as single-strand
breaks (SSBs) and double-strand breaks (DSBs) [5]. DNA
repair is, however, just one arm of the broad DNA damage
response (DDR). The DDR is an elaborate signaling network
that swiftly modulates many physiological processes; it consti-
tutes one of the most comprehensive cellular responses tonces and
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power of the DDR has come mainly from studies of the
response to the DNA DSB – an extremely cytotoxic DNA
lesion that vigorously activates the DDR [7].
The relationship between genome stability and human
health is highlighted by the genome instability syndromes.
Patients with these syndromes are typically characterized by
progressive degeneration of specific tissues, chromosomal
instability, cancer predisposition, and increased sensitivity to
DNA damaging agents [8–10]. Predisposition to specific types
of cancers can be conferred by heterozygosity for mutations
that inactivate certain DDR components, such as p53, breast
cancer type 1 susceptibility protein (BRCA1), breast cancer
type 2 susceptibility protein (BRCA2), and mismatch repair
(MMR) proteins [11–13]. These phenotypes highlight the inti-
mate link between genome instability and the formation and
progression of cancers [4,14]. It has recently become evident
that variations in DDR efficiency contribute to the develop-
ment of metabolic and cardiovascular diseases [15,16]. It is
our notion that combinations of sequence alterations in
DDR genes account for a continuum of variation in genome
stability in the human population that affects public health
on a large scale.
Mutations in key DDR molecules are implicated in human
genomic instability syndromes [17]. These disorders include
ataxia-telangiectasia (A-T, mutation in the ATM gene encod-
ing ataxia-telangiectasia mutated) [18], ataxia-telangiectasia-
like disorder (A-TLD, mutation in meiotic recombinant 11
homolog; MRE11) [19], Seckel syndrome (mutation in ataxia
telangiectasia and Rad3 related; ATR) [20], and Nijmegen
breakage syndrome (NBS, mutation in nibrin NBS1) [21].
Patients suffering from A-T, A-TLD, or NBS exhibits symp-
toms involving neural and lymphoid organs. A-TLD patients
generally have a slower progression of disease than A-T
patients do [22,23]. NBS patients have a phenotype on the cel-
lular level similar to A-T, except that cerebellar defects are dif-
ferent [21,24–27]. The phenotype of the Seckel syndrome
overlaps with some features of A-T, A-TLD, and NBS (e.g.,
microcephaly, mental retardation, genomic instability, and
hematological malignancies). Patients with each of these dis-
eases have neurological defects, suggesting that the DDR is
important in neurogenesis and neurodegeneration.
A-T – a brain degenerative disease caused by genome
instability
Malfunctioning DDR is implicated in many human brain
degenerative diseases (BDDs) [28] including the prototypical
genome instability syndrome A-T. The hallmarks of A-T are
severe neuro-motor dysfunction (emanating primarily from
progressive cerebellar atrophy), telangiectasia (formation of
small dilated blood vessels), immunodeficiency, sterility, a
striking predisposition to lymphoid malignancies, extreme sen-
sitivity to ionizing radiation, and, in some patients, growth
retardation, premature aging, as well as insulin-resistant dia-
betes [29–31]. Cerebellar ataxia is one of the most devastating
symptoms of A-T and progressively develops into general
motor dysfunction [32]. One of the main causes of death of
A-T patients is aspiration due to cerebellar-related swallowing
defects [33]. Post-mortem studies reveal a significant loss of
Purkinje and granule neurons in the cerebellums of youngA-T patients, and therefore this disease was once considered
a ‘‘Purkinje cell disease” [34,35]. The observed damage to cere-
bellar neurons due to the loss of the ATM gene supports the
‘‘neuron doctrine” thought to underlie neurodegenerative dis-
eases. Cellularly, A-T is characterized by cerebellar degenera-
tion of various cell types, premature senescence of
fibroblasts, chromosomal instability, and hypersensitivity to
DNA-damaging agents, particularly those that induce DSBs
[36]. Such increased sensitivity results from a profound defect
in the cellular response to DSBs, which in normal cells chiefly
mobilize ATM kinase [8].
Malfunctioning DDR affects brain functionality
ATM deficiency is a representative of genomic instability dis-
orders that severely affect brain functionality. Thus, we will
focus on ATM deficiency and its effects on neuronal and glial
cell functionality. Neurons contain significant levels of ATM
in the cytoplasm [37]. The cytoplasmic ATM is found in synap-
tosomes, the synaptic termini of neurons, where it forms
a complex with synaptobrevin (also known as vesicle-
associated membrane protein 2, VAMP2) and synapsin-I.
Synaptobrevin is part of a complex structure know as soluble
N-ethylmaleimide-sensitive factor activating protein receptor
(SNARE) that mediates synaptic vesicle fusion with the cell
membrane during the release of neurotransmitters, while
synapsin-I is an abundant neuronal phosphoprotein that is
associated with synaptic vesicles [38]. Interestingly, both
synaptobrevin and synapsin-I must be phosphorylated in order
to bind ATM [37]. ATM deficiency leads to reduced long-term
potentiation (LTP) at the Schaffer collateral-CA1 pathway,
suggesting a role for cytoplasmic ATM [37].
It is highly likely that information coding in the brain is not
performed at the level of single neurons but rather at the level
of neural-glial networks [39]. Many BDDs are characterized by
malfunctioning DDR, and it is important to understand how
malfunctioning DDR influences the dynamics of neural-glial
networks. Using microelectrode arrays to simultaneously
record data from many neurons, Levine-Small et al. [40] ana-
lyzed how ATM deficiency affected the dynamics of neural-
glial networks. Interestingly, no differences in firing activity
between individual wild-type and ATM-deficient neurons were
detected in response to DNA damage. In contrast, ATM
deficiency led to a decrease in synchronization persistence
compared to wild-type cortical networks following
chemically-imposed DNA damage. These findings support
the notion that neurological symptoms are not always the pro-
duct of the malfunction of one cell but rather result from the
failure of interacting networks. Thus, an additional implica-
tion of the study by Levine-Small et al. is that understanding
the systems-level network is critically important for general
comprehension of BDDs and for the development of treatment
modalities for brain illness.
In a quest to understand the role of ATM in the activity of
Purkinje cells, Chiesa et al. conducted morphological and elec-
trophysiological analyses of Purkinje cells from ATM/ mice
of different ages [41]. No histological or immunohistochemical
abnormalities were found in these mice. Electrophysiological
analyses revealed no abnormalities in resting membrane poten-
tial, input resistance, or anomalous rectification. However,
significant reductions in the durations of calcium and sodium
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sured. The calcium deficit became significant between the ages
of 6–8 and 12–20 weeks and appeared to be progressive. Volt-
age clamp recording showed that the firing deficits are due to a
significant decrease in calcium currents, whereas the inactivat-
ing potassium currents were unaffected [41]. Taken together,
these results indicate that ATM deficiency severely affects cere-
bellar functionality.
In addition to cerebellar defects in ATM-deficient mice, sev-
ere deficiencies are found in the retina of ATM/ mice, which
affect retinal neurons, vascular system, and retinal electrical
activity. Retinal neurons are terminally differentiated and have
the highest metabolic activity of all neurons in the central ner-
vous system (CNS) [42]. This makes them highly susceptible to
DNA damage, which in turn severely disrupts cell metabolism.
The retinal neurons are highly dependent on glial-vascular sup-
port. ATM deficiency leads to reduced integrity of the retinal
vasculature, which was associated with increased levels of vas-
cular endothelial growth factor (VEGF) and of fibrinogen [43].
In addition, ATM deficiency reduces the levels of cell adhesion
molecules such as occludin and consequently leads to retinal
micro–hemorrhages [43]. Morphological analyses of wild-
type and ATM-deficient retinal astrocytes reveal structural
alterations in ATM-deficient cells [43]. Amplitude aberrations
were observed in 2-month-old ATM/ mice, which pro-
gressed to significant functional deficits in the older mice.
Taken together, these findings suggest that hampered vascular-
ization and astrocyte–endothelial cell interactions in the CNS
have an important role in the etiology of A-T and that vascular
abnormalities likely aggravate brain degeneration.
Brain functionality is highly dependent on astrocytes. Mal-
functioning astrocytes can cause many brain diseases [44,45]
including NBS. Conditional inactivation of NBS1 in the
CNS (NBS1-D-CNS) leads to severe cerebellar atrophy charac-
terized by reduced number of Purkinje cells [46]. Furthermore,
there are reduced levels of cerebellar granule neurons as well as
microglial cells in these mice [47]. It is of note that these mice
exhibit the reduced astrocytic functionality as evidenced by
reduced levels of glutamine synthetase, brain-derived neu-
rotrophic factor (BDNF), and neurotrophic factor 3 (NT3)
[47].
Glial cells: central players in brain homeostasis and
functionality
Until very recently, brain function was thought to be mainly
dependent on neuronal cells. The ‘‘neuron doctrine”, which
has governed modern brain research since the late 19th century
[48,49], portrayed neurons as the basic information processing
unit of the nervous system, implying that neurodegenerative
disorders are diseases of neurons. Because of this, most, if
not all, A-T neurological research has focused mainly on Purk-
inje cells, granule neurons, dopaminergic neurons, but ignoring
other types of CNS cells [50]. Recent studies lead to the idea
that glial cells are critical to brain function. Over the course
of evolution of the brain, there are many changes involving
glial cells [51]. It has been estimated that protoplasmic astro-
cytes in the human neocortex are threefold larger in size and
have tenfold more primary processes as compared to their
rodent counterparts [51,52]. Most importantly, astrocytes
in higher primates display a much larger complexity ascompared, for example, with those of rodents. Protoplasmic
astrocytes derived from human brains manifest a threefold lar-
ger diameter and have tenfold more primary processes than
those of rodents [51]. It has been estimated that every human
protoplasmic astrocyte contacts and enwraps 2 million
synapses compared to only 100,000 synapses covered by
the processes of a mouse astrocyte [51]. Interestingly, the dif-
ference in the morpho-physiological complexity of neurons
between humans and other species is relatively small. For
example, the density of synaptic contacts in the brains of
rodents and humans is roughly the same at around
1–1.4  109 mm3 [51]. The differences between human astro-
cytes and those of rodents are summarized in Table 1.
During the past 20 years, knowledge regarding the appear-
ance, physiological properties, and functions of glial cells has
grown tremendously [53]. Accumulating evidence clearly
shows that glial cells (and especially astrocytes) are as diverse
as neurons. The micro-architecture of the brain matter is
shaped by glial cells [54]. Many of the receptors and channels
expressed in glial cells are functionally similar to those of neu-
rons. Glial cells can release gliotransmitters, enabling them to
form communicating networks capable of long-range informa-
tion exchange. They also respond to synaptic inputs; and,
finally, they can act as pluripotent neural precursors for adult
neurogenesis [55]. Astrocytes are active partners in synaptic
function, integrating and processing synaptic information, as
well as influencing synaptic transmission and plasticity [56].
The current understanding of gliobiology constitutes a chal-
lenge to the ‘‘neuron doctrine”, and fundamentally reshapes
our perception of brain organization, which undeniably will
lead to a more inclusive theory of brain function.
For many years BDDs have been thought to be primarily
associated with dysfunction or death of neural cells. However,
emerging evidence points to dysfunction in neuron-glia commu-
nications as playing a large role [57]. Indeed, it appears that glia
cells (astrocytes in particular) are much more than just the
‘‘glue” that holds together the neurons of the CNS. Rather, glia
are very active participants in the neuronal network. Glia can
release ‘‘gliotransmitters” and have many of the same receptors
as neurons, indicating that glia and neurons can speak and com-
prehend the same chemical language [54]. Accordingly, it no
longer makes sense to consider networks of neurons in isola-
tion, since neurons and glia act in concert to form the circuits
and networks of the CNS. Given the importance of neuron-
glia communications, and the insights stemming from a large
body of previous studies, it is reasonable to assume that dys-
functional neuron-glia communications play a major role in
BDDs that result from a malfunctioning DDR.
Astroglial cells function under both normal and pathologi-
cal conditions. Under normal physiological conditions, astro-
glial cells control water movement and distribution, as well
as buffer the concentrations of extracellular potassium ions.
They are capable of regulating the release of neurotrophic fac-
tors as well as extracellular concentrations of neurotransmit-
ters released from neighboring synapses. One of the most
important roles of glial cells is the neutralization of ROS gen-
erated in the vicinity of various types of cells including neu-
rons. Astrocytes are important for metabolic support of
adjacent neurons. They do so by absorbing glucose from blood
vessels that they contact and converting it to lactate, which is
then provided to neurons (Figure 1). The functionality of
astrocytes is impaired under pathological conditions. Stressed
Table 1 Evolutionary alterations in human astrocytes compared to rodents
Glial parameter Rodent Human
Glia to neuron ratio 1 4.1-fold greater
Number of processes 1 10-fold greater
Process length (protoplasmic) 1 2.6-fold greater
Process diameter 1 2.9-fold greater
Cell diameter (protoplasmic) 1 2.6-fold greater
Cell diameter (fibrous) 1 2.14-fold greater; similar in shape
Cell volume (protoplasmic) 1 27-fold greater; much more complex
Number of supported synapses 1 20-fold greater
Propagation of calcium waves 1 4-fold faster
Average area of overlap domains 1 2.8-fold greater
Summated area of overlapping domains 1 3.8-fold greater
Note: The table was generated based on the data presented previously [51,52].
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Figure 1 The physiological roles of glia cells
Brain homeostasis is critically dependent on the functionality of the glial cells. As depicted in the figure and as described in the text,
astrocytes are involved in many brain functional processes such as the regulation of the vascular system and the blood–brain barrier,
metabolic control, maintenance of homeostatic redox state and buffering of electrolytes, as well as control of water distribution. In
addition, astrocytes control synaptogenesis and synaptic pruning. Microglial cells control brain immunological responses, phagocytose
dying cells as well as various debris, and are responsible for synaptic pruning through the complement system. Oligodendrocytes regulate
axonal myelination. BBB, brain blood barrier; GS, glutamine synthetase; ROS, reactive oxygen species.
158 Genomics Proteomics Bioinformatics 14 (2016) 155–165astrocytes can no longer control water movement and as a con-
sequence can lead to brain edema. Malfunctioning astrocytes
can also generate toxic levels of ROS such as hydroxyl radi-
cals, nitric oxide, and peroxynitrite [57–59].
Astrocytes are also involved in various aspects of synapto-
genesis, synaptic maturation, neurotransmitter homeostasis,
brain microcirculation, brain metabolism, as well as control
over formation and maintenance of the blood–brain barrier
[60–73]. In addition, ‘sick or stressed’ astrocytes can reversethe direction of certain neurotransmitter transporters, thereby
releasing substances such as glutamate, concomitant with
secretion of cytotoxic levels of Ca2+. Increased intracellular
Ca2+ levels can activate calcium-dependent cysteine proteases
(calpains), thereby causing neural demise [74]. Failure to buffer
extracellular K+ concentrations promotes further over-
excitation of neuronal cells [58]. Stressed astrocytes can
affect the aforementioned processes. Like neurons, astrocytes
can communicate with surrounding cells through plasma
Kaminsky N et al / Glial Functionality and Brain Degenerative Diseases 159membrane channels, transporters, receptors, and certain mole-
cules and by undergoing exocytosis or endocytosis [75–81].
The effects of DNA damage on astroglial cell
functionality
Whereas neuronal cells are highly differentiated and post-
mitotic cells, mature astrocytes in the brain are capable of cell
proliferation [82,83]. As mitotic cells, one would assume that
DNA damage in astrocytes could be repaired through either
homologous recombination (HR) or non-homologous end
joining (NHEJ), depending on the mitotic phase of the cell.
Adams et al. measured the rate of DNA DSB repair in human
embryonic stem cells (hESCs), neural progenitors, and astro-
cytes. They showed that generation of cH2AX in hESCs was
slower than in neural progenitors and astrocytes, suggesting
that DSB repair in hESCs is more complex compared to that
in neural progenitors and astrocytes [84]. It seems that the
activity of HR repair is highest in hESCs and declines as a
function of differentiation with little activity detected in neural
progenitors and no trace of activity detected in astrocytes.
Interestingly, ATM plays a major role in NHEJ and a minor
role in HR repair in stem cells. These results may provide an
explanation regarding the progressive nature of A-T and
why the absence of ATM does not lead to embryonic lethality.
ATM seems to be very important for DSB repair in fully-
differentiated astroglial cells [85]. ATM deficiency in the brain
impairs the functionality of the neuro-glio-vascular unit.
Unlike mature and fully-differentiated astrocytes, glioblas-
toma cells retain their ability to activate HR repair. There is a
dose-dependent increase of Rad51 focus formation in response
to the induction of DSBs in glioblastoma cells. Down-
regulation of Rad51 expression using RNAi is associated with
increased cell death following ionizing radiation (IR) treat-
ment [86]. Schneider et al. [85] compared DDR activation
and radio-resistance between somatic stem cells and
terminally-differentiated descendant astrocytes. They showed
that somatic neural stem cells display robust activation of
the canonical DDR following exposure to IR as measured
by the formation of phosphorylated ATM nuclear foci and
the phosphorylation of ATM substrates p53 and cH2AX. In
vitro and in vivo observations revealed that compared to
somatic stem cells, ATM activation and its downstream
DDR factors such p53, checkpoint kinase 2 (CHK2), and
ATR are strongly inhibited in astrocytes compared to somatic
stem cells. The inhibition of the DDR machinery involves a
stable transcriptional repression of key DDR genes as men-
tioned above. The astroglial cells examined in this investiga-
tion are non-proliferative mature terminally-differentiated
cells, mimicking the state of most of adult astroglial cells.
Interestingly, astrocytes retain the expression of NHEJ genes
and are proficient in DNA repair. It seems that upon DNA
damage induced by IR, DNA-dependent protein kinase
DNA-PK, a PI3K-like kinase, is responsible for cH2AX signal
in astrocytes [85]. ATR plays similar roles as DNA-PK in neu-
ronal stem cells [84]. Together, these results suggest that at dif-
ferent developmental stages, ATM, ATR and DNA-PK are all
responsible for H2AX phosphorylation in response to IR.
FOXO3a, the main FOXO transcription factor isoform
expressed in astrocytes, is responsible for the cellular response
to oxidative stress. This is achieved by regulating theexpression of specific genes, including those genes encoding
factors involved in DNA repair and glutamine metabolism
such as glutamine synthetase. Immunohistochemical analyses
of human samples from the population-based neuropathology
cohort of the Medical Research Council’s Cognitive Function
and Ageing Study have shown that the FOXO3a nuclear
retention significantly correlates with DDR and with glu-
tamine synthetase expression by astrocytes [87]. Moreover, a
correlation between the expression of glutamine synthetase
and Alzheimer’s disease-type pathology in this aging cohort
was observed. Taken together, these findings suggest that in
astrocytes glutamine synthetase serves a neuroprotective mech-
anism and is affected by nuclear retention of FOXO3a in
response to oxidative stress [87].
Using a variety of cellular, molecular, and genomic
methodologies, Yong et al. [88] showed that IR-induced
DNA damage repair pattern at the gene locus-specific level
and genome-wide level changes along with the alteration of
transcriptional state of human astrocytes. Interestingly, fol-
lowing IR, the activity of DNA repair in actively-transcribed
chromatin is increased in reactive astrocytes, compared to
non-reactive astroglial cells. The authors mapped the repair
sites and identified misrepaired events and repaired hotspots
that were unique to each transcriptional state. In addition,
Swain and Rao evaluated the DNA damage at the single-cell
level in isolated neurons and astrocytes derived from rats of
different ages [89]. They found the increased DNA damage
in both neurons and astrocytes with advancement of age, in
view of SSBs, DSBs, 8-oxoguanine (8-oxoG), as well as sites
sensitive to 8-oxoG glycosylase (OGG1) and uracil DNA gly-
cosylase. Furthermore, the authors provided evidence for age-
dependent decreases in the activities of DNA repair enzymes of
the base excision repair (BER) pathway. Collectively, these
results show that aging affects both neurons and astrocytes
through the decline of many cellular repair mechanisms.
Phosphatase and tensin homolog (PTEN) acts as a tumor
suppressor [89]. Unlike most of the protein tyrosine
phosphatases, PTEN preferentially dephosphorylates
phosphoinositide substrates such as phosphatidylinositol
(3,4,5)-triphosphate (PIP3) resulting in PIP2. PTEN is involved
in the regulation of the cell cycle, preventing cells from grow-
ing and dividing too rapidly [89]. In addition, PTEN has a role
in DSB repair. Exposure of PTEN-null astrocytes to
N-methyl-N0-nitro-N-nitrosoguanidine, a functional analog of
temozolomide, results in the accumulation of DSBs due to
inefficient DNA repair and apoptosis [90]. PTEN deletion also
compromises HR repair. It is possible that PTEN inactivation
increases astrocyte proliferation and that the HR repair path-
way is activated in proliferating astrocytes, although it is inac-
tivated in non-dividing astrocytes. The compromised HR
repair in PTEN-deficient astrocytes can be explained by
reduced expression Rad51 paralogs.
Glial cell alterations in primary cultures derived from
ATM/ cerebella
Glial fibrillary acidic protein (GFAP) is an astrocyte-specific
marker. Compared to wild type, there is a less complex cell
arborization in ATM/ cerebellar neural-glial networks as
revealed by GFAP staining; the number of branches
originating from the cell bodies is also significantly lower in
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marked reduction in GFAP expression in cerebellar sections
from ATM-deficient mice, suggesting that ATM deficiency
leads to reduced levels of valete astrocytes in vivo. Similarly,
morphological alterations in astrocytes are found in ATM-
deficient retinas and optic nerves. Reduced arborization of
the retina and optic nerve is associated with reduced retinal
functionality as shown by electroretinographic examination
[43]. These findings suggest that impaired astrocytic function-
ality in the CNS plays an important role in the etiology of
A-T.The functional role of microglia in health and disease
In the year 1919, Rio Hortega described a new type of glial
cell, the microglia [91]. These cells descend from the
hematopoietic system, invade the brain early during develop-
ment, and become the resident immune system of the CNS.
Nonetheless, not much was known about their functionality
in health and disease for decades. In the past 10 years, our
knowledge about microglia functionality has been tremen-
dously increased due to thorough studies of various brain dis-
orders as well as injuries [92]. Our current view of microglial
cells is that these cells are major players in the brain defense
system against various types of biological threats as well as
injuries [93]. Morphologically, microglia behave like chame-
leons and change their forms from a resting state with many
processes to an activated macrophage-like state (ameboid) in
response to a variety of stimuli [94]. In a state of injury or dis-
ease, and following the secretion of various chemokines by
astrocytes, microglial are swiftly recruited to the damage sites
where they phagocytose or engulf various types of cellular deb-
ris and remove dying or unnecessary cells. In addition to their
immune response to trauma or infection, microglial cells are
capable of secreting neurotoxic proteins and cytokines that
contribute to pathological inflammation [95,96]. In 2010,
Ginhoux et al. showed that microglial cells develop from prim-
itive myeloid progenitors that arise before embryonic day 8 to
invade the brain [97]. These findings challenge the current
dogma that microglia develop from peripheral macrophages.
The data reported by Ginhoux et al. suggest that the microglia
are ontogenically a population of mononuclear phagocytic
cells [97]. New evidence implicates microglia in building and
wiring of the developing CNS, through functions that range
from neurogenesis to synaptic pruning [98,99].DDR in microglia
Alkylating agents, such as methylnitrosourea (MNU), severely
affect mitochondrial DNA (mtDNA). In response to MNU,
there are no cell-specific differences in initial mtDNA damage
repair in different glial cells including microglia, astrocytes,
and oligodendrocytes. However, compared to astrocytes,
mtDNA repair in oligodendrocyte progenitors, oligodendro-
cytes, and microglia was significantly reduced. A variety of
xenobiotics can lead to mitochondrial perturbations, which
would culminate in apoptosis. Whereas MNU-treated oligo-
dendrocytes display DNA laddering and other characteristics
of apoptosis, no signs of apoptosis are detected in astrocytes
exposed to MNU [100].Carcinogenesis and neurodegeneration can be caused by
ROS lesions that lead to the formation of 8-oxoG. Severe stri-
atal neurodegeneration is detected in mice lacking genes
encoding 7,8-dihydro-8-oxoG triphosphatase (MTH1) that
prevents the incorporation of 8-oxo-20-deoxyguanosine
triphosphate to the DNA and/or OGG1 that excises 8-oxoG.
In contrast, mice deficient in mutY homolog (MUTYH)
and/or OGG1 are resistant to neurodegeneration induced by
oxidative stress. Together, these findings indicate that
MUTYH, a glycosylase involved in oxidative DDR, promotes
neurodegeneration, whereas OGG1 and MTH1 are protective.
Accumulation of 8-oxoG in neuronal mtDNA leads to
calpain-dependent neuronal loss. This process is associated
with delayed 8-oxoG nuclear accumulation in microglial cells
leading to PARP-dependent activation of apoptosis-inducing
factor and exacerbated microgliosis. Taken together, these
findings show accumulation of 8-oxoG in the genomes of neu-
rons and microglia results in neurodegeneration [101].
Alterations in microglia have been suggested to contribute
to age-related CNS deterioration. Enhanced sensitivity to
various inflammatory stimuli is among the most prominent
age-related changes in microglial cells, which is referred to as
priming. During microglial priming, microglia multiply and
adopt an activated state in response to neurodegeneration
and abnormally folded proteins [102]. Whether microglial cell
priming is an intrinsic microglial aging process or induced by
the aging neural environment is not clear. DNA excision repair
protein 1 (Ercc1) mutant mice, which display DNA repair defi-
ciencies, serve as a good model for accelerated aging. These
mutant mice show the accelerated aging in various tissues
including the brain. Hallmarks of microglial priming such as
cytokine expression and phagocytosis can be detected in the
Ercc1 mutant mice in response to peripheral lipopolysaccha-
ride. Progressive priming response of microglial cells is also
observed in mice with Ercc1 deleted in forebrain neurons, in
association with phenotypic alterations [103].
In human Alzheimer’s disease patients, elevated S-
adenosylhomocysteine (SAH) is found in plasma and cerebral
tissue, which is inversely correlated with the cognitive ability
of the patients [104]. Moreover, treatment of BV2 cells (mouse
immortalized microglia) with SAH causes DNA hypomethyla-
tion, irreversible DNA damage, and cytotoxicity [105]. This
appears to be attributed to the inhibition of DNA methyltrans-
ferase 1 (DNMT1) by SAH. Interestingly, exposure of the BV2
cells to SAH also leads to increased level of amyloid beta, which
then lead to the generation of ROS, increased levels of 8-oxoG,
and reduced expression of OGG1 [106].
(+)-Catechin, a flavanol antioxidant extracted from Acacia
catechu [107], efficiently inhibits tert-butylhydroperoxide-
induced DNA damage and cell death. Huang et al. have shown
that down regulation of p53 phosphorylation following (+)-
catechin treatment decreases the levels of hydroxyl radicals
and cell cycle arrest. The reduced p53 activity follows the impair-
ment of NF-jB translocation to the nuclear region [108].
NBS1 inactivation compromises the functionality of
astrocytes
Hypomorphic mutations in the NBS1 locus lead to the mental
retardation, microcephaly, radiation sensitivity, chromosomal
instability, immunodeficiency, and cancer predisposition
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formed by the association of Mre11, Rad50, and NBS1. The
complex is involved in sensing cell cycle checkpoints and DSBs
[109]. Early embryonic lethality is observed NBS1 – null mice,
making it difficult to study the physiological functions of
NBS1 during development [110,111].
We hypothesized that NBS1 deletion specifically in astro-
cytes would affect the DDR and thereby cause cerebellar
pathology and behavior. We generated the GFAP-Cre-lox
mouse strain with down-regulated expression of the NBS1
specifically in astrocytes (Binyamini H et al., in preparation).
These NBS1-GFAP-D astrocytes displayed reduced function-
ality as well as malfunctioning DDR in response to X-ray irra-
diation or the radiomimetic agent neocarzinostatin. Compared
to wild-type cells, expression of BDNF and glutamine syn-
thetase (GS) is reduced in the NBS1-deficient astrocytes. Inter-
estingly, there is no evidence of altered cerebellar morphology
in 10 month-old NBS1-GFAP-D mice, which seem to have
normal behavior. Therefore, the observed malfunction DDR
may not be sufficient to cause pathological effects. It is also
possible that NBS1 deletion in one cell population is not suffi-
cient to cause cerebellar pathology (Binyamini H, personal
communication).
Reduced microglia recruitment results from
conditional deletion of NBS1 in the CNS
CD11b encodes an integrin expressed specifically in microglia
[47]. CD11b expression is significantly reduced in NBS1-
CNS-D cerebella, together with reduced levels of cysteine–cys-
teine chemokine ligand 2 (CCL2), the chemokine primarily
responsible for attracting CD11b-positive cells and mediating
the innate immune response in the CNS [112]. Other than that,
expression of the gene encoding cysteine–cysteine chemokine
receptor 2 (CCR2) is significantly downregulated in NBS1-
CNS-D cerebella in comparison with wild-type mice [47]. It is
of note that a CCR2-deficiency accelerates the severity of
BDDs and markedly impairs microglial cell accumulation in
the mouse brain [113].
Malfunctioning DDR affects brain functionality via
glial cell impairment
How does malfunctioning DDR affect glial cell functionality
and thereby network dynamics? Glial cells are key players in
neuronal homeostasis through the following processes, includ-
ing metabolic support [114–116], regulation of neuro- and glio-
transmitters uptake and release, secretion of neurotrophic
factors, synaptogenesis, synaptic maintenance, and synaptic
pruning [71,117–119] (Figure 1).
Network dynamics is heavily dependent on network topol-
ogy, the connections among neural cells, the interactions
between neurons and glial cells, and on the mode of synaptic
transmission. Malfunctioning DDR severely affects the glial
cell functionality, and malfunctioning astrocytes can alter
synaptic activity, thereby affecting the dynamics of neural-
glial networks. Alterations in K+ ion buffering and water dis-
tribution can also affect neural activity, influencing network
dynamics. The excitatory neurotransmitter glutamate and thesupply of glutamine to surrounding neural cells are also impor-
tant for network functionality. Our results clearly demonstrate
that NBS1 deletion reduces the secretion of neurotrophic fac-
tors and reduces expression of glutamine synthetase, the
enzyme responsible for conversion of glutamate to glutamine
[47]. In addition to astrocytes, microglial cells are also vital
for brain functionality. Malfunctioning DDR reduces the abil-
ity of astrocytes to recruit microglial cells, thereby stripping
the brain of an important protective layer. We have shown that
glial cells are capable of controlling a variety of processes that
can affect network dynamics. Based on the available data, we
still do not know, however, how glial-controlled processes
affect network dynamics.
Closing remarks
The brain is the most complicated tissue in higher organisms,
responsible for control of vital processes and also at the center
of motor functions, cognition, and personality. Loss of brain
functions through trauma or aging exacts an enormous human
toll on patients and families. Cases of age-related dementia
have increased as average life spans have reached record highs.
Moreover, advances in modern medicine have enabled us to
replace or repair almost all body organs except the brain. To
ensure that brain functionality can be maintained in old age,
it is critically important to gain a better understanding of the
cellular and molecular processes involved in the brain dysfunc-
tion that can result from BDDs (Figure 2).
For many years the neuronal doctrine has dominated the
field of brain research, but it is now clear that various types
of glial cells are critical to brain function. Like neurons, the
glial cell population contains a vast variety of cells, each with
a different role. Glial cells are important in the most rudimen-
tary synaptic processes and in the regulation of complex brain
networks and circuitries. Some glial cells provide the structure
necessary for CNS development, others provide nutrients to
support neurons, and others appear essential to activities such
as the formation of synaptic connections and pruning. Some
glial cells undertake immune system functions, such as the
destruction of invading pathogens. Such an important role is
performed by the microglial cells that invade the brain during
embryonic development.
As mentioned in this review, much of the gliobiology
research has focused upon astrocytes and microglia, which
have very broad portfolios of responsibilities and contribu-
tions. These two populations of glial cells form highly-
complex connections, which are disrupted during brain
pathologies. Structurally, astrocytes are very complex and their
activation has been reported in a variety of brain diseases and
injuries. The specific functions of astrocytes under physiologi-
cal as well as in pathological conditions are still not completely
understood. This is due in part to the enormous heterogeneity
of glial cells starting from stem cells and ending in mature
highly polarized and differentiated cells. Naturally, this makes
the comparison of individual studies rather difficult [120].
A common denominator in various BDDs is malfunction-
ing of DDR pathways. Here we present evidence that impaired
DDR severely affects the functionality of glial cells and under-
lies the symptoms of certain degenerative diseases of the brain.
Based on a wealth of data, we suggest that glial cells play a
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Figure 2 The role of glial cells in brain degenerative diseases
Malfunctioning glial cells are involved in a variety of brain diseases as depicted in the figure and the text. DDR, DNA damage response;
ALS, amyotrophic lateral sclerosis. The figure was drawn based on the data presented previously [57].
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